How have CERS and DMAC total returns compared?

Over the past 10 years, CERS delivered -9.37% and DMAC delivered 7.89% annualized total return. Past performance doesn't predict future results.

Cerus Corporation (CERS) vs DiaMedica Therapeutics Inc. (DMAC)

A side-by-side comparison of Cerus Corporation and DiaMedica Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CERS

Cerus Corporation

$472M

$2.34HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

DMAC

DiaMedica Therapeutics Inc.

$454M

$8.42HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CERS vs DMAC

growth of $100 · dividends reinvested · last 10y

CERS -62.6% (-9.4%/yr)DMAC +113.7% (+7.9%/yr)DMAC compounded faster over this window

Log scale — wide-divergence pair

CERS DMAC

CERS vs DMAC: by the numbers

•CERS is the larger company ($472M vs $454M market cap).
•Both run net losses; DMAC's is the smaller (0.00% vs -3.06% net margin).

Metrics side by side

Valuation

Metric	CERS	DMAC
P/S ratio	2.13	N/A
P/B ratio	6.73	11.83
EV / EBITDA	8036.17	N/A

Profitability

Metric	CERS	DMAC
Gross margin	52.05%	0.00%
Operating margin	-0.73%	0.00%
Net margin	-3.06%	0.00%
ROE	-9.69%	-97.92%
ROIC	-1.08%	-100.87%

Growth (annualized)

Metric	CERS	DMAC
Revenue CAGR (5Y)	15.74%	N/A
Total return CAGR (5Y)	-17.30%	16.41%

Frequently asked

How have CERS and DMAC total returns compared?: Over the past 10 years, CERS delivered -9.37% and DMAC delivered 7.89% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CERS analysis Full DMAC analysis Interactive comparison tool

Dig into the metrics

Cerus ROE DiaMedica Therapeutics ROE Cerus operating margin DiaMedica Therapeutics operating margin Cerus revenue growth DiaMedica Therapeutics revenue growth Cerus free cash flow DiaMedica Therapeutics free cash flow

Cerus & DiaMedica Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.